TY - JOUR
T1 - Clinical characteristics and treatment outcomes of carbapenem-resistant Enterobacterales infections in Japan
AU - Japan Infection Prevention and Control Conference for National and Public University Hospitals
AU - Oka, Keisuke
AU - Matsumoto, Akane
AU - Tetsuka, Nobuyuki
AU - Morioka, Hiroshi
AU - Iguchi, Mitsutaka
AU - Ishiguro, Nobuhisa
AU - Nagamori, Tsunehisa
AU - Takahashi, Satoshi
AU - Saito, Norihiro
AU - Tokuda, Koichi
AU - Igari, Hidetoshi
AU - Fujikura, Yuji
AU - Kato, Hideaki
AU - Kanai, Shinichiro
AU - Kusama, Fumiko
AU - Iwasaki, Hiromichi
AU - Furuhashi, Kazuki
AU - Baba, Hisashi
AU - Nagao, Miki
AU - Nakanishi, Masaki
AU - Kasahara, Kei
AU - Kakeya, Hiroshi
AU - Chikumi, Hiroki
AU - Ohge, Hiroki
AU - Azuma, Momoyo
AU - Tauchi, Hisamichi
AU - Shimono, Nobuyuki
AU - Hamada, Yohei
AU - Takajo, Ichiro
AU - Nakata, Hirotomo
AU - Kawamura, Hideki
AU - Fujita, Jiro
AU - Yagi, Tetsuya
N1 - Funding Information:
This study was funded by a grant from the Ministry of Health, Labour and Welfare (Research No: H28-Shinkogyousei-Ippan-004), research on emerging and re-emerging infectious diseases and immunisation, and grants from SHIONOGI & Co., Ltd., and MSD K.K.
Funding Information:
These results were presented at the 31st ECCMID, the European Congress of Clinical Microbiology and Infectious Diseases, which took place online from 9 July to 12 July 2021 (abstract number 01755). We would like to thank Shinya Nirasawa (Sapporo Medical University School of Medicine), Yuki Sato (Sapporo Medical University School of Medicine), Mizuho Sato (Niigata University), Seiya Kashiyama (Hiroshima University Hospital), Masami Sato (Tokushima University Hospital), Shinobu Murakami (Ehime University Hospital), Hitoshi Miyamoto (Ehime University Hospital), and Keiichi Yamamoto (Kumamoto University) for the collection of clinical data and CRE isolates. This study was funded by a grant from the Ministry of Health, Labour and Welfare (Research No: H28-Shinkogyousei-Ippan-004), research on emerging and re-emerging infectious diseases and immunisation, and grants from SHIONOGI & Co. Ltd. and MSD K.K. The Institutional Review Board at Nagoya University Hospital approved the study (approval number 2017-0320).
Publisher Copyright:
© 2022 The Author(s)
PY - 2022/6
Y1 - 2022/6
N2 - Objectives: The dissemination of difficult-to-treat carbapenem-resistant Enterobacterales (CRE) is of great concern. We clarified the risk factors underlying CRE infection mortality in Japan. Methods: We conducted a retrospective, multicentre, observational cohort study of patients with CRE infections at 28 university hospitals from September 2014 to December 2016, using the Japanese National Surveillance criteria. Clinical information, including patient background, type of infection, antibiotic treatment, and treatment outcome, was collected. The carbapenemase genotype was determined using PCR sequencing. Multivariate analysis was performed to identify the risk factors for 28-day mortality. Results: Among the 179 patients enrolled, 65 patients (36.3%) had bloodstream infections, with 37 (20.7%) infections occurring due to carbapenemase-producing Enterobacterales (CPE); all carbapenemases were of IMP-type (IMP-1: 32, IMP-6: 5). Two-thirds of CPE were identified as Enterobacter cloacae complex. Combination therapy was administered only in 46 patients (25.7%), and the 28-day mortality rate was 14.3%. Univariate analysis showed that solid metastatic cancer, Charlson Comorbidity Index ≥3, bloodstream infection, pneumonia, or empyema, central venous catheters, mechanical ventilation, and prior use of quinolones were significant risk factors for mortality. Multivariate analysis revealed that mechanical ventilation (OR: 6.71 [1.42–31.6], P = 0.016), solid metastatic cancers (OR: 5.63 [1.38–23.0], P = 0.016), and bloodstream infections (OR: 3.49 [1.02–12.0], P = 0.046) were independent risk factors for 28-day mortality. Conclusion: The significant risk factors for 28-day mortality in patients with CRE infections in Japan are mechanical ventilation, solid metastatic cancers, and bloodstream infections.
AB - Objectives: The dissemination of difficult-to-treat carbapenem-resistant Enterobacterales (CRE) is of great concern. We clarified the risk factors underlying CRE infection mortality in Japan. Methods: We conducted a retrospective, multicentre, observational cohort study of patients with CRE infections at 28 university hospitals from September 2014 to December 2016, using the Japanese National Surveillance criteria. Clinical information, including patient background, type of infection, antibiotic treatment, and treatment outcome, was collected. The carbapenemase genotype was determined using PCR sequencing. Multivariate analysis was performed to identify the risk factors for 28-day mortality. Results: Among the 179 patients enrolled, 65 patients (36.3%) had bloodstream infections, with 37 (20.7%) infections occurring due to carbapenemase-producing Enterobacterales (CPE); all carbapenemases were of IMP-type (IMP-1: 32, IMP-6: 5). Two-thirds of CPE were identified as Enterobacter cloacae complex. Combination therapy was administered only in 46 patients (25.7%), and the 28-day mortality rate was 14.3%. Univariate analysis showed that solid metastatic cancer, Charlson Comorbidity Index ≥3, bloodstream infection, pneumonia, or empyema, central venous catheters, mechanical ventilation, and prior use of quinolones were significant risk factors for mortality. Multivariate analysis revealed that mechanical ventilation (OR: 6.71 [1.42–31.6], P = 0.016), solid metastatic cancers (OR: 5.63 [1.38–23.0], P = 0.016), and bloodstream infections (OR: 3.49 [1.02–12.0], P = 0.046) were independent risk factors for 28-day mortality. Conclusion: The significant risk factors for 28-day mortality in patients with CRE infections in Japan are mechanical ventilation, solid metastatic cancers, and bloodstream infections.
KW - Carbapenem-resistant Enterobacterales
KW - Carbapenemase-producing Enterobacterales
KW - Mortality
KW - Risk factors
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=85129937984&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85129937984&partnerID=8YFLogxK
U2 - 10.1016/j.jgar.2022.04.004
DO - 10.1016/j.jgar.2022.04.004
M3 - Article
C2 - 35429667
AN - SCOPUS:85129937984
SN - 2213-7165
VL - 29
SP - 247
EP - 252
JO - Journal of Global Antimicrobial Resistance
JF - Journal of Global Antimicrobial Resistance
ER -